Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease

Alzheimer's Disease Clinical Trial

— SUN-AK  

Official title:

Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00951834
• Other study ID #: SUN-AK
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: October 2009
• Est. completion date: February 2015

Study information

• Verified date: July 2021
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

EGCG has shown a neuroprotective effect in cell-experimental and animal studies. The neuroprotective mechanism of EGCG probably bases - besides the known antioxidant effect - amongst others on the modulation of several signal transduction pathways, the influence on the expression of genes which regulate cell survival resp. programmed cell death, as well as the modulation of the mitochondrial function. In different Alzheimer models EGCG seems to cause an induction of alpha-secretase and the endothelin-converting-enzyme, as well as to prevent the aggregation of beta-amyloid to toxic oligomers through the direct binding to the unfolded peptide.

The investigators therefore expect EGCG to have a positive influence on the course of the Alzheimer´s Disease.

Description:

Alzheimer's disease (AD) is a progressive dementia characterised by an ongoing loss of memory function and of at least one additional cognitive domain resulting in impairment of daily life functioning. Treatment of diseases such as diabetes mellitus, fractures and cardiovascular diseases is more expensive and complicated in patients with dementia compared to those without. The yearly costs for treatment and care of AD patients in the US are estimated to exceed 100 billion USD. Life expectancy is reported to be about 10 years after establishment of the diagnosis and is significantly reduced compared to non-demented subjects of similar age and socio-economic status.

Age is the most relevant risk factor for AD, followed by genetic factors. Prevalence is less than 1% amongst individuals aged 50-60, but is reported to double every 5 years beyond the age of 60. The prevalence exceeds 30% in the age of 85-90.

The only standard therapy for AD are acetylcholine-esterase inhibitors (AchEI; donepezil, galantamine, rivastigmine). AchEI exhibit a temporary stabilizing mild effect on the progression of AD. Conversion rates from "mild cognitive impairment" to AD do not seem to be beneficially influenced by AchEI. A high percentage of premature study withdrawals owing to adverse events has been observed in AchEI studies published to date. The questionable benefit may further be outweighed by high costs of the AchEI.

Therefore, there is a necessity for the development of more efficacious and less expensive disease-modifying drugs with a better safety and tolerability profile. EGCG is a promising compound which has proven efficacious in AD animal models and which has shown an excellent tolerability in our 18-month clinical trial on Multiple Sclerosis currently being performed at our institution (SuniMS study, NCT00525668).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• early stage of AD (Diagnosis DSM-IV and NINCDS/ADRDA, Dubois-criteria 2007)

• age 60-100

• MMSE 20-26

• patient lives at home with at least one relative who perform external ratings/assessment

• co-medication with Donepezil (Aricept®, Pfizer Pharma GmbH) with at least 3 months to maximum 6 months of existing stable medication

• maximum of 2 cups of black tea/die, no green tea, not more than > 500 ml/die of grapefruit juice

Exclusion Criteria:

• co-medication with NSAIDs (longterm medication) (ASS is not an exclusion criteria), Gingko- or other natural extracts, other anti-dementiva except of Donepezil

• familial autosomal-dominant inherited AD

• instable medical condition

• other primary psychiatric/neurologic disorders

• missing informed consent

• no readiness to save and refer pseudonym personal data

• hospitalisation due to juridical or legal regulation

• any condition disturbing or making MRI and other measures impossible

• clinically relevant GI-disorders at screening and 1 year before

• clinically relevant lung, infectious, heart or other CNS disorders, clinical or paraclinical suspicion of TBC, history of vascular CNS-disorders at screening and 1 year before

• clinically relevant liver disorders at screening and 1 year before

• clinically relevant functional disorders of liver, kidney or bone marrow defined by following lab values at screening:

• Marrow dysfunction:

• HB < 8,5 g/dl

• WBC < 2,5/nl

• Thrombocytes < 125/nl

• Kidney dysfunction:

• Creatinin-Clearance according to Cockcroft-Gault-Formula: Cl < 110ml/min (male) resp. Cl < 95ml/min (female), from the age of 30 decline of 10ml/min per decade

• Liver dysfunction:

• ASAT/ALAT > 3.5 x higher than the upper reference value

• Bilirubin > 2.0 mg/dl

• known allergy of elements of Sunphenon EGCg or additives of Sunphenon EGCg resp. placebo

• long-term hepatotoxic medication

• current intake of cytochrom P450 3A4-inhibitors or -inductors, such as antimycotics of the azol-type or macrolide-antibiotics

• clinical-anamnestic or paraclinical manifestations suggesting an alcohol or drug abuse

• participation in any clinical trial < 3 months prior to screening or ongoing

• any medical, psychiatric or other condition which might constrain the ability of the patient to understand the informed consent, to give consent, to adhere to the protocol or to accomplish the study

• massive and extended sun exposure

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• Epigallocatechin-Gallate
Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg: Months 1-3: 200 mg EGCG/die (200-0-0 mg) Months 4-6: 400 mg EGCG/die (200-0-200 mg) Months 7-9: 600 mg EGCG/die (400-0-200 mg) Months 10-18: 800 mg EGCG/die (400-0-400 mg)
• Placebo
Placebo

Locations

Country	Name	City	State
Germany	Charité Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie	Berlin
Germany	Charite University Medicine Berlin	Berlin
Germany	Klinik für Neurologie	Ulm

Sponsors (1)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ADAS-COG (Score 0-70) (Baseline to treatment)		18 months
Secondary	Safety and tolerability of the verum		18 months
Secondary	MMSE (Score 0-30) after 18 months compared to baseline		18 months
Secondary	Time to hospitalisation and Time to death related to AD		18 months
Secondary	Brain atrophy assessed by brain MRI		18 months
Secondary	Baseline-ADAS-COG and Baseline-MMSE as covariates		18 months
Secondary	CIBIC+ and WHO-QOL-Bref		18 months
Secondary	Trail Making Test and MVGT		18 months

External Links

•   Related Info